Evolus Inc at Barclays Global Healthcare Conference Transcript
My name is Balaji Prasad. I'm the senior analyst for the spec pharma coverage. Continuing our sessions for this afternoon. We have with us the management team from Evolus. So Sandra Beaver, the CFO; and Rui Avelar, Chief Medical Officer with us. And Sandra and Rui, you just recently had your earnings release call. Maybe why don't you recap, scoping the key points from the earnings and then jump into Q&A from there.
Sure. Sounds great. Thank you also for having us here. Thanks to everyone. Just last week, we did our Q4 earnings announcement. We put up 49% growth for 2022 revenue, ending the year at $149 million. We achieved our guidance target of top end of $140 million to $150 million of revenue. Had $137 million for cost, which is also at the low end of our operating cost guidance. We're really pleased with the results, really pleased with the level of growth we're seeing in the market in 2022. We also reiterated our 2023 guidance where we had guided to $180
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |